Efficacy of Topiramate in Children with Refractory Status Epilepticus
dc.contributor.author | Kahriman, Mustafa | en_US |
dc.contributor.author | Minecan, Daniela | en_US |
dc.contributor.author | Kutluay, Ekrem | en_US |
dc.contributor.author | Selwa, Linda M. | en_US |
dc.contributor.author | Beydoun, Ahmad A. | en_US |
dc.date.accessioned | 2010-04-01T14:54:58Z | |
dc.date.available | 2010-04-01T14:54:58Z | |
dc.date.issued | 2003-10 | en_US |
dc.identifier.citation | Kahriman, Mustafa; Minecan, Daniela; Kutluay, Ekrem; Selwa, Linda; Beydoun, Ahmad (2003). "Efficacy of Topiramate in Children with Refractory Status Epilepticus." Epilepsia 44(10): 1353-1356. <http://hdl.handle.net/2027.42/65372> | en_US |
dc.identifier.issn | 0013-9580 | en_US |
dc.identifier.issn | 1528-1167 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/65372 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14510830&dopt=citation | en_US |
dc.description.abstract | Purpose: Status epilepticus (SE) is a life-threatening medical condition associated with significant morbidity and mortality that requires urgent medical intervention. Although several agents are available to treat SE, they occasionally fail to abort seizure activity. Topiramate (TPM) was anecdotally reported to be effective in adult patients with refractory SE. In this study, we evaluated the efficacy of TPM administered to children with this condition. Methods: We retrospectively reviewed the pediatric SE database at the University of Michigan Medical Center and identified three children with refractory SE who were treated with TPM. Those children failed to respond to treatment with benzodiazepines, phenytoin, phenobarbital, midazolam, or pentobarbital. Additional treatment with TPM was administered by nasogastric tube. All patients were continuously monitored by 21-channel digital EEG machines, and the diagnosis of SE was made by a board-certified neurophysiologist. Results: The ages of the three children were 4.5 months, 34 months, and 11 years. TPM was initiated at 2 mg/kg/day in two children and at 3 mg/kg/day in the third. The status was terminated in all three children within 24 h of maintenance therapy with TPM at 5–6 mg/kg/day. Conclusions: These results support the potential efficacy of TPM for children with refractory SE. Larger prospective series are needed to confirm those results. | en_US |
dc.format.extent | 84567 bytes | |
dc.format.extent | 3110 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2003 International League Against Epilepsy | en_US |
dc.subject.other | Topiramate | en_US |
dc.subject.other | Safety | en_US |
dc.subject.other | Status Epilepticus | en_US |
dc.subject.other | Efficacy | en_US |
dc.subject.other | Antiepileptic Drugs | en_US |
dc.title | Efficacy of Topiramate in Children with Refractory Status Epilepticus | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan, U.S.A. | en_US |
dc.identifier.pmid | 14510830 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/65372/1/j.1528-1157.2003.11803.x.pdf | |
dc.identifier.doi | 10.1046/j.1528-1157.2003.11803.x | en_US |
dc.identifier.source | Epilepsia | en_US |
dc.identifier.citedreference | Scott RC, Surtees RAH, Neville BGR. Status epilepticus: pathophysiology, epidemiology, and outcomes. Arch Dis Child 1998 ; 79 : 73 – 7. | en_US |
dc.identifier.citedreference | DeLorenzo RJ, Pellock JM, Towne AR, et al. Epidemiology of status epilepticus. J Clin Neurophysiol 1995 ; 12 : 316 – 25. | en_US |
dc.identifier.citedreference | Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. Arch Dis Child 2000 ; 83 : 415 – 9. | en_US |
dc.identifier.citedreference | Mayer SA, Claasen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002 ; 59 : 205 – 10. | en_US |
dc.identifier.citedreference | Shorvon S. Status epilepticus: its clinical features and treatment in children and adults. Cambridge : Cambridge University Press, 1994. | en_US |
dc.identifier.citedreference | Sahin M, Menache CC, Holmes GL, et al. Outcome of severe refractory status epilepticus in children. Epilepsia 2001 ; 42 : 1461 – 7. | en_US |
dc.identifier.citedreference | Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000 ; 41 ( suppl 1 ): S3 – 9. | en_US |
dc.identifier.citedreference | Reuber M, Evans J, Bamford JM. Topiramate in drug-resistant complex partial status epilepticus [Letter]. Eur J Neurol 2002 ; 9 : 111 – 2. | en_US |
dc.identifier.citedreference | Towne AR, Garnett LK, Waterhause EJ, et al. The use of topiramate in refractory status epilepticus. Neurology 2003 ; 60 : 332 – 4. | en_US |
dc.identifier.citedreference | Kim SJ, Lee DY, Kim JS. Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. Pediatr Neurol 2002 ; 25 : 217 – 20. | en_US |
dc.identifier.citedreference | Yang Y, Shuaib A, Li Q, et al. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998 ; 804 : 169 – 76. | en_US |
dc.identifier.citedreference | Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999 ; 837 : 263 – 9. | en_US |
dc.identifier.citedreference | Cha BH, Silveira DC, Liu X, et al. Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res 2002 ; 51 : 217 – 32. | en_US |
dc.identifier.citedreference | Martin R, Kuzniecky R, Ho S, et al. Cognitive side effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999 ; 52 : 321 – 7. | en_US |
dc.identifier.citedreference | Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001 ; 42 : 1134 – 40. | en_US |
dc.identifier.citedreference | Glauser TA, Miles MV, Tang P, et al. Topiramate pharmacokinetics in infants. Epilepsia 1999 ; 40 : 788 – 91. | en_US |
dc.identifier.citedreference | Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial onset seizures in children. Neurology 1999 ; 52 : 1338 – 44. | en_US |
dc.identifier.citedreference | Ritter F, Glauser TA, Elterman RD, et al. Effectiveness, tolerability, and safety of topiramate in children with partial onset seizures. Epilepsia 2000 ; 41 ( suppl 1 ): S82 – 5. | en_US |
dc.identifier.citedreference | Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000 ; 41 ( suppl 1 ): S91 – 4. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.